What were the vibes like at BIO 2026? STAT reporters take you inside the annual industry conference on the latest episode of ...

Biotech executives reveal concerns over Chinese biotech, the profitability of AI, and the durability of Trump's drug price ...

Merck KGaA agreed to buy Bio-Techne Corporation for $11.3 billion to bolster its life-science business, marking the German ...

Passage Bio, the Philadelphia-based gene therapy outfit that launched a strategic review earlier this year after tough feedback from the FDA, has found an exit in an ...

The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene therapy pioneer ...

Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin ...

Bio-Techne rallied for a third straight day on Thursday, surging 20.08 percent to close at $70.70 apiece, as investors ...